Teva Pharmaceutical Industries (TEVA) Shares Outstanding (Weighted Average) (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Shares Outstanding (Weighted Average) across 18 years of filings, most recently posting $1.2 billion for Q1 2026.

• Quarterly Shares Outstanding (Weighted Average) rose 1.58% year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 1.58% YoY) and the FY2025 annual result came in at $1.1 billion, up 1.24% from the prior year.
• Shares Outstanding (Weighted Average) improved to $1.2 billion in Q1 2026, from $1.1 billion in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $1.2 billion in Q1 2026 and troughed at $1.1 billion in Q1 2022.
• A 5-year average of $1.1 billion and a median of $1.1 billion in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) grew 0.54% — and 2026, when it climbed 1.58%.
• Tracing TEVA's Shares Outstanding (Weighted Average) over 5 years: stood at $1.1 billion in 2022, then advanced by 0.81% to $1.1 billion in 2023, then climbed by 1.07% to $1.1 billion in 2024, then grew by 1.24% to $1.1 billion in 2025, then rose by 0.96% to $1.2 billion in 2026.
• Business Quant data shows TEVA's Shares Outstanding (Weighted Average) at $1.2 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.